Hillsdale Investment Management Inc. Increases Stock Position in Halozyme Therapeutics, Inc. $HALO

Posted by George Bondi on May 31st, 2026

Hillsdale Investment Management Inc. increased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO – Free Report) by 14.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 107,450 shares of the biopharmaceutical company’s stock after buying an additional 13,450 shares during the quarter. Hillsdale Investment Management Inc.’s holdings in Halozyme Therapeutics were worth $7,231,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Empowered Funds LLC bought a new position in Halozyme Therapeutics during the 1st quarter valued at $755,000. Acadian Asset Management LLC bought a new position in Halozyme Therapeutics during the 1st quarter valued at $195,000. Hsbc Holdings PLC boosted its stake in Halozyme Therapeutics by 117.1% during the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock valued at $522,000 after acquiring an additional 5,448 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in Halozyme Therapeutics by 6.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 174 shares during the last quarter. Finally, Baird Financial Group Inc. boosted its stake in Halozyme Therapeutics by 6.2% during the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock valued at $577,000 after acquiring an additional 650 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have commented on the stock. HC Wainwright increased their price objective on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. Benchmark increased their price objective on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Finally, Wells Fargo & Company increased their price objective on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. Seven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $80.67.

Read Our Latest Report on HALO

Insiders Place Their Bets

In other Halozyme Therapeutics news, CEO Helen Torley sold 10,000 shares of the stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $69.19, for a total transaction of $691,900.00. Following the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $53,122,698.20. This represents a 1.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 8,857 shares of the stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $67.64, for a total transaction of $599,087.48. Following the sale, the chief operating officer directly owned 7,055 shares in the company, valued at $477,200.20. This trade represents a 55.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 120,482 shares of company stock valued at $8,200,842. Company insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Stock Down 2.4%

Shares of NASDAQ:HALO opened at $66.54 on Friday. The stock has a market capitalization of $7.89 billion, a price-to-earnings ratio of 23.94, a price-to-earnings-growth ratio of 0.27 and a beta of 0.89. Halozyme Therapeutics, Inc. has a 1-year low of $51.06 and a 1-year high of $82.22. The company’s fifty day moving average is $66.14 and its two-hundred day moving average is $68.76. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76.

Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last issued its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. The company had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm’s revenue was up 42.2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities analysts anticipate that Halozyme Therapeutics, Inc. will post 7.6 EPS for the current year.

Halozyme Therapeutics Company Profile

(Free Report)

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.